Collaboration and Other Agreements - (Tables)

3 Months Ended

Mar. 31, 2015

Collaboration and Other Agreements [Abstract]

Schedule of Revenue Related to Collaboration and License Arrangements

Total collaboration services and milestone revenue recognized with respect to the Agreement consisted of the following (in thousands):



	Three Months Ended
	March 31,
	2015		2014
Collaboration services and other revenue	$	4,089	$	3,135
License and milestone revenue	—		60,000
Total	$	4,089	$	63,135

On a worldwide basis, Pharmacyclics' share of total pre-tax profit (loss) under the Agreement was calculated as follows:



	Three Months Ended
	March 31,
	2015			2014
50% of Pharmacyclics' U.S. product revenue, net	$	94,579		$	28,090
Less: 50% of Pharmacyclics' U.S. cost of goods sold	(8,351		)	(3,055		)
Pharmacyclics' share of U.S. net product revenue less cost of goods sold	86,228			25,035
Less: Pharmacyclics' share of U.S. commercial expenses under the Agreement	(15,083		)	(14,593		)
Pharmacyclics' share of U.S. pre-tax profits from the commercialization of IMBRUVICA under the Agreement	71,145			10,442
Add: Pharmacyclics' share of ex-U.S. pre-tax commercial profit (loss) under the Agreement ⁽¹⁾	12,525			(3,572		)
Pharmacyclics' share of worldwide pre-tax profits from the commercialization of IMBRUVICA under the Agreement	83,670			6,870
Less: Pharmacyclics' share of worldwide R&D expenses under the Agreement	(27,332		)	(24,402		)
Total pre-tax profit (loss) under the Agreement	$	56,338		$	(17,532	)

⁽¹⁾For the three months ended March 31, 2015, the Company's share of ex-U.S. pre-tax commercial profit under the Agreement was classified as alliance revenue, net in the condensed consolidated statements of operations. For the three months ended March 31, 2014, the Company's share of ex-U.S. pre-tax commercial loss under the Agreement was classified within selling, general and administrative expenses in the condensed consolidated statements of operations.

Schedule of Collaborative Arrangements, Recognized Costs

Expenses which were charged to the collaboration for the three months ended March 31, 2015 and 2014 are as follows (in thousands):



	Three Months Ended
	March 31,
	2015			2014
Collaboration expenses, unadjusted	$	37,590		$	32,365
Increase (decrease) for cost sharing	(10,258		)	(7,963		)
Research and development, net	$	27,332		$	24,402

Collaboration expenses, unadjusted	$	20,730		$	18,220
Increase (decrease) for cost sharing	(5,647		)	(55		)
Selling, general and administrative, net	$	15,083		$	18,165